市場調查報告書
商品編碼
1020427

炭疽菌疫苗的全球市場:成長,趨勢,COVID-19的影響,預測(2021年∼2026年)

Anthrax Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

炭疽菌疫苗的市場規模,在預測期間內預計以7.85%的年複合成長率成長。

所有市場都受到COVID-19突然爆發的重大影響,重點已主要轉移到對抗COVID-19上,所有其他研發都被擱置。許多政府機構還建議優先考慮對診所和醫院的緊急訪問。因此,Covid-19預計將對炭疽疫苗市場產生輕微的負面影響。

市場成長主要歸因於諸如炭疽流行率增加和未煮熟或生肉消費量增加等因素。炭疽是一個嚴重的公共衛生問題,在受影響的國家具有很高的經濟意義。

儘管市場由有限的參與者主導,並且預計將在預測期內成長,但對診斷和篩查測試的認識不足以及炭疽疫苗的成本過高等因素可能會限制市場成長。

本報告提供炭疽菌疫苗的世界市場調查,市場概要,市場成長要素及阻礙因素分析,市場機會,COVID-19的影響,各疫苗類型、應用、渠道的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場推動因素
    • 全球炭疽負擔加重
    • 未煮熟/生肉消費量增加
  • 市場阻礙因素
    • 缺乏對目標疾病診斷檢測的認識
    • 疫苗相關的高成本
  • 波特的五力分析

第5章 市場區隔

  • 各疫苗類型
  • 各應用
  • 各渠道

第6章 競爭情形

  • 企業簡介
    • AdvaCare Pharma
    • Fresenius SE &Co. KGaA
    • Genesis BPS.
    • Grifols SA
    • Haemonetics Corporation
    • HLL Lifecare Limited
    • INNVOL
    • JMS Co., Ltd.
    • Kawasumi Laboratories, Inc.
    • MacoPharma
    • Neomedic International
    • Poly Medicure Limited
    • Span Healthcare Private Limited
    • Teleflex Incorporated
    • Terumo Corporation

第7章 市場機會及趨勢

目錄
Product Code: 72130

The anthrax vaccine market is expected to project growth with an estimated CAGR of 7.85% during the forecast period.

All the markets were majorly impacted by the sudden outbreak of COVID-19. With the focus primarily shifted to combat COVID-19, all other research and development are put on hold. In July 2020, the Center for Disease Control and Prevention (CDC) had provided certain guidelines to veterinary professionals for the treatment of animals during COVID-19. Along with these, many government agencies have recommended prioritizing urgent and emergency visits to clinics and hospitals. Thus, COVID-19 is expected to have a slight negative impact on the anthrax vaccine market.

The studied market growth is largely attributed to factors, such as the increasing prevalence rate of anthrax and rising consumption of undercooked or raw meat. Anthrax is a serious public health problem and causes high economic significance in affected countries. Enhancing surveillance, diagnosis, and outbreak response may help to prevent it in both animals and humans. The prevalence rate of disease is high, the risk and severity of infection make it one of the priority list diseases for preventive healthcare agencies. In December 1999, the Centers for Disease Control and Prevention (CDC) launched the Anthrax Vaccine Research Program (AVRP) and continue working till now to encourage studies about cost-effective, next-generation anthrax vaccines and measure the ability for provoking an immunological response. Anthrax from contaminated meat has been reported in animals as well. Furthermore, according to the Agricultural Economic Insights (AEI) report, meat consumption in the United States increased in 2020 when studied from 1970 to 2020. Although consumption pattern largely varies in poultry, beef, and pork, it increases the risk of anthrax. Thus, concerning the above facts, the anthrax vaccine market is expected to grow over the forecast period.

Although the market is dominated by limited players and expected to grow in the forecast period, factors, such as less awareness about diagnostic and screening tests and the cost-prohibitive nature of the anthrax vaccine, may restrict the market growth.

Key Market Trends

Animal Use Anthrax Vaccination Segment is Expected to Dominate the Market Over the Forecast Period

Anthrax is an epizootics disease spread from animals to humans and emerges periodically among susceptible animals, either wild or domesticated. In herbivore animals, like cattle, sheep, goats, camels, and antelopes, anthrax is acute septicemia with a high fatality rate and is usually accompanied by hemorrhagic lymphadenitis. On the other hand, it is a less acute but potentially fatal disease in dogs, pigs, and horses. The appearance of the outbreak may be associated with drought, flood, or soil disturbances. Humans got anthrax infection when they encountered infected animals or their processed materials, like wool, processed hair, etc. The annual vaccination is required in animals before 2-4 weeks of the season when the outbreak is expected. Many anthrax vaccines are used for animals and all of which are un-encapsulated live variant vaccines. The live vaccines used for animals require a withholding period to slaughter for human consumption, which varies from 3-6 weeks depending on the vaccine used. Additionally, Bacillus anthracis spores have been used earlier as biologic warfare agents and are a threat to both animal and human populations. Therefore, vaccination in animals, particularly in livestock, is considered a vital tool for preventing and controlling anthrax cases both in animals and humans.

North America Holds Significant Share in the Market and Expected to Grow in Forecast Period

Anthrax is most common in agricultural regions with calcareous soil and has been reported almost in every continent. In North America, anthrax infection is rare. According to the United States Food and Drug Administration (USFDA) February 2018 report, the mortality rates vary according to the exposure. It is 20% for cutaneous anthrax without antibiotics, for gastrointestinal anthrax, it can 25-75%. The fatality rate could 80% or higher for inhalational anthrax. The major sources of infection in humans are direct contact with infected animals, animal products. The effective vaccination for adults of 18-65 age by Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston with occupational risk of anthrax exposure. Due to the lethality of disease and potential bioterrorism agents, vaccination is highly needed. Therefore, federal agencies are continuously taking steps to prevent anthrax and focus mainly on vaccination programs. Further, according to the priority pathogen list, July 2018, Bacillus Anthracis is a Category A priority pathogen developed by the National Institute of Allergy and Infectious Disease (NIAID), the United States which implies it poses the highest risk to National security. Thus, North America is encouraging participates to enter in North America Market by focusing more on preventive healthcare facilities.

Competitive Landscape

The anthrax vaccine market is consolidated with a limited number of players both in the human and animal segments. In terms of market share, major players dominate the market. With the rising prevalence of disease and increasing awareness among the public, many new players may enter the market over the forecast period. Some major market players under the human anthrax vaccine segment are Emergent Bio Solutions, Altimmune, and Proton Biopharma Ltd, while the animal segment of the market is dominated by Colondo Serum Company, Zoetis Inc, and Bayer AG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Anthrax Globally
    • 4.2.2 Increased Consumption of Undercooked/Raw Meat
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness for Diagnostic Test of Target Disease
    • 4.3.2 High Cost Associated with Vaccine
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Vaccine Type
    • 5.1.1 Cell Free PA Vaccine
      • 5.1.1.1 Anthrax Vaccine Absorbed (AVA)
      • 5.1.1.2 Anthrax Vaccine Precipitated (AVP)
    • 5.1.2 Live Attenuated Vaccine
  • 5.2 By Applications
    • 5.2.1 Animal Use
    • 5.2.2 Human Use
  • 5.3 By Distribution Channel
    • 5.3.1 Hospitals
    • 5.3.2 Pharmacies
    • 5.3.3 Other Distribution Channels
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Emergent Bio Solutions
    • 6.1.2 Altimmune (PharmAthene Inc.)
    • 6.1.3 Proton Biopharma Ltd
    • 6.1.4 Colondo Serum Company
    • 6.1.5 Merck & Co. Inc.
    • 6.1.6 Bayer AG
    • 6.1.7 Zoetis Inc.
    • 6.1.8 Indian Immunologics
    • 6.1.9 Agrovet
    • 6.1.10 Biogenesis Bago
    • 6.1.11 Tiankang

7 MARKET OPPORTUNITIES AND FUTURE TRENDS